IRVINE, Calif.--(BUSINESS WIRE)--NeurOptics, Inc., the leading provider of devices that collect and process information from the human eye to facilitate medical decision-making, announced the appointment of William Worthen as president. Worthen will be responsible for continuing the company’s progress in making the NeurOptics® Pupillometer and NPi™ (Neurological Pupil index™) algorithm the standard of care in providing objective, consistent assessment of pupil size and light reactivity in patients with serious neurological injuries.
Worthen brings more than 30 years of extensive sales, marketing, and management experience to his new position, having previously served as president and CEO of several neurocritical care companies, including Silk Road Medical, Alsius Corp., and Neuro Navigational Corp. He also held sales and marketing management positions with American Hospital Supply (Edwards Labs), Trimedyne, and Intertherapy, medical device companies focused on cardiovascular medicine, critical care, and interventional cardiology.
“Bill’s depth of knowledge and experience in the neurocritical care industry will be invaluable as we work to increase adoption of the NeurOptics Pupillometer as a critical part of neurological assessment in patients with traumatic brain injury, stroke, and other neurological injuries,” said Kamran Siminou, CEO of NeurOptics. “NeurOptics Pupillometers are currently being used by more than 100 hospitals, including many leading academic medical centers, and Bill’s leadership will help to ensure that all appropriate patients have access to this important technology.”
“I am excited to join the NeurOptics team and look forward to developing our company’s technology as a standard of care,” Worthen said. “NeurOptics Pupillometers add an important dimension to clinical assessment by providing an objective measurement of pupillary response, helping clinicians detect subtle pupil changes and allowing earlier intervention, with the goal of improving patient outcomes.”
The NeurOptics Pupillometer is a hand-held, cordless device that removes subjectivity and variability in the measurement of pupil size and the pupillary light reflex. The device uses infrared imaging technology to take and analyze more than 30 pictures per second of the pupil’s response to light stimulus. Results are displayed on a color LCD screen—for the first time providing a numeric indication of whether a patient’s pupillary response falls within or outside a normal range as defined by the NeurOptics NPi algorithm.
About NeurOptics
NeurOptics, Inc., based in Irvine, Calif., provides devices that collect and process information from the human eye to facilitate medical decision-making and enable clinical research. The company offers the NPi™-100 Pupillometer used in critical care and emergency medicine, as well as pupillometers for ophthalmic surgery and research. The company’s pupillometers are being used by a growing number of leading hospitals and stroke centers across the country. For more information, visit www.neuroptics.com.
